• Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact

Barry A. Friedman, PhD LLC

FDA Regulatory Compliance for the Pharmaceutical, Biotechnology and Medical Device Arenas

FDA Warning Letters – Their Relationship to Drug Shortages

June 12, 2014 By Barry Friedman Leave a Comment

The FDA has become keenly aware within the past several years of the impact that their audits have on the availability of drugs becoming available to the consuming public.  Douglas C. Throckmorton, MD, Deputy Director for Regulatory Affairs, CDER, FDA recently presented at the ISPE meeting on June 4, 2014 where he discussed this and illustrated the “FDA Response to Drug Shortages”.

Within his presentation, he discusses 1) shortages as a significant public health threat; 2) FDA’s role in drug shortages; 3) recent FDA activities; and 4) future FDA directions.  He noted that the three primary sources of drug shortages include Quality manufacturing issues of 1) Quality: facility remediation efforts (35%); 2) Quality: product manufacturing issues (31%), and 3) discontinuation of product (14%).  Examples of Quality manufacturing issues included sterility, particulates, crystallization, precipitation, etc.

For sterile injectables, he noted that the state of industry was an issue because a small number of manufacturers make up most of the market, a lack of redundant manufacturing, complex manufacturing processes, and very inexpensive products (in some situations).

It was noted that an Executive Order from President Obama directed the FDA to use its authorities to encourage early notification of potential shortages.  It became particularly obvious within any Warning Letters that were issued within the past several years.  As a result, close to 200 drug shortages were prevented in 2011 and more than 280 in 2012.  Injectables were a large percentage of those averted in the time frame of 2010-2013.  The two primary notification sources for sterile injectable drugs were manufacturers (40%) and FDA inspections (43%).

To review the Strategic Plan and learn of the Future of Drug Shortages, please review the following web site that contains all of the slides presented as well as illustrated graphics.  Please visit: http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM400503.pdf?source=govdelivery&utm_medium=email&utm_source=govdelivery

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)

Related

Filed Under: FDA Compliance, Regulatory Compliance, Warning Letters Tagged With: CDER, drug shortages, injectables, manufacturing, Sterility, Throckmorton, Warning Letter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

New Reader? Learn More

Connect With Me:

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Webinar Registration & Information

FREQUENTLY ASKED QUESTIONS:

FDA Form 483 Frequently Asked Questions

USP General Chapter

USP General Chapter 62, Part II

TOP OBSERVATIONS:

FDA’s CDER LISTING OF TOP NINETEEN OBSERVATIONS FOR 2014

FDA CDER Most Frequent Form FDA 483 Observations Fiscal Year 2012

CDER MOST FREQUENTLY CITED DRUG OBSERVATIONS – FISCAL YEAR 2010

Top Posts:

Top Posts for 2012

Top Posts for 2013

Top Posts Year To Date

Recent Posts

  • Upcoming Microbiological Webinars
  • Microbiological Webinars
  • Microbiological Webinars 2020 (Upcoming)
  • General Chapter (USP<60>) on B. cepacia Complex to Issue December 1, 2019
  • Les Produits Chimiques B.G.R., Inc. Receives FDA Warning Letter (07/24/2018) for Failure to Perform Laboratory Testing

Categories

follow us in feedly
  • Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Thank You For Visiting Barry A. Friedman, PhD LLC - 2015

Welcome To My Blog!
Please enter your name and email below to receive my newsletter.
Your information will *never* be shared or sold to a 3rd party.